Percutaneous Closure of Patent Ductus Arteriosus

Percutaneous-based patent ductus arteriosus closure is technically feasible among infants less than 1.5  kg. However, marked heterogeneity in the type and nature of adverse events obscures current safety profile assessments. Although data on the risks of postdevice closure syndrome remain promising, a lack of comparative trials of surgical ductal ligation and inconsistent surveillance across publishe d studies obscure confidence in present estimates of safety and efficacy. To minimize risk and yield the greatest benefits, clinical studies of patent ductus arteriosus treatment should consider incorporating more robust assessments to ensure that infants at greatest risk for adverse ductal conseque nces are included.

Source: Clinics in Perinatology - January 21, 2022 Category: Perinatology & Neonatology Authors: Megan Barcroft, Christopher McKee, Darren P. Berman, Rachel A. Taylor, Brian K. Rivera, Charles V. Smith, Jonathan L. Slaughter, Afif El-Khuffash, Carl H. Backes Source Type: research